Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $65.0 million.

  • Arcus Biosciences' Other Non-Current Assets fell 1333.33% to $65.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 1333.33%. This contributed to the annual value of $73.0 million for FY2024, which is 3113.21% down from last year.
  • As of Q3 2025, Arcus Biosciences' Other Non-Current Assets stood at $65.0 million, which was down 1333.33% from $69.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Other Non-Current Assets ranged from a high of $116.0 million in Q4 2021 and a low of $2.0 million during Q1 2021
  • In the last 5 years, Arcus Biosciences' Other Non-Current Assets had a median value of $73.0 million in 2024 and averaged $63.7 million.
  • As far as peak fluctuations go, Arcus Biosciences' Other Non-Current Assets skyrocketed by 175718.86% in 2021, and later tumbled by 3119.27% in 2024.
  • Over the past 5 years, Arcus Biosciences' Other Non-Current Assets (Quarter) stood at $116.0 million in 2021, then decreased by 1.72% to $114.0 million in 2022, then dropped by 7.02% to $106.0 million in 2023, then tumbled by 31.13% to $73.0 million in 2024, then fell by 10.96% to $65.0 million in 2025.
  • Its last three reported values are $65.0 million in Q3 2025, $69.0 million for Q2 2025, and $71.0 million during Q1 2025.